EW Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 14.91%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Boston Scientific Corp.'s return on equity of 12.46%.

Edwards Lifesciences Corp. has a consensus price target of $95.80, signalling upside risk potential of 10.31%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.02%. Given that Boston Scientific Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Boston Scientific Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Edwards Lifesciences Corp.'s net income of $292.3M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.97x while Boston Scientific Corp.'s PE ratio is 51.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.68x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 15.47%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Globus Medical, Inc.'s return on equity of 10.08%.

Edwards Lifesciences Corp. has a consensus price target of $95.80, signalling upside risk potential of 10.31%. On the other hand Globus Medical, Inc. has an analysts' consensus of $98.73 which suggests that it could grow by 11.67%. Given that Globus Medical, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Globus Medical, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 7.046%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Globus Medical, Inc.'s net income of $119M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.97x while Globus Medical, Inc.'s PE ratio is 28.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.68x versus 4.40x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pulse Biosciences, Inc. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of -22540.7%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Pulse Biosciences, Inc.'s return on equity of -73.32%.

Edwards Lifesciences Corp. has a consensus price target of $95.80, signalling upside risk potential of 10.31%. On the other hand Pulse Biosciences, Inc. has an analysts' consensus of $22.00 which suggests that it could grow by 52.78%. Given that Pulse Biosciences, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Pulse Biosciences, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Pulse Biosciences, Inc. has a beta of 1.806, suggesting its more volatile than the S&P 500 by 80.579%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Pulse Biosciences, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Pulse Biosciences, Inc. quarterly revenues of $86K. Edwards Lifesciences Corp.'s net income of $292.3M is higher than Pulse Biosciences, Inc.'s net income of -$19.4M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.97x while Pulse Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.68x versus 11,044.59x for Pulse Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 18.82% compared to Edwards Lifesciences Corp.'s net margin of 14.18%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Stryker Corp.'s return on equity of 14.06%.

Edwards Lifesciences Corp. has a consensus price target of $95.80, signalling upside risk potential of 10.31%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.86%. Given that Stryker Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Stryker Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.968, which suggesting that the stock is 3.229% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Edwards Lifesciences Corp.'s net income of $292.3M is lower than Stryker Corp.'s net income of $859M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 36.97x while Stryker Corp.'s PE ratio is 46.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 8.68x versus 5.61x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.